These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12950526)

  • 1. Pure class III agents for prevention of sudden cardiac death.
    Pratt CM
    J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S82-6. PubMed ID: 12950526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The azimilide post-infarct survival evaluation (ALIVE) trial.
    Camm AJ; Karam R; Pratt CM
    Am J Cardiol; 1998 Mar; 81(6A):35D-39D. PubMed ID: 9537221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias.
    Reiffel JA
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):333-9. PubMed ID: 11907635
    [No Abstract]   [Full Text] [Related]  

  • 4. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azimilide dihydrochloride: a unique class III antiarrhythmic agent.
    Tran HT
    Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties.
    Nattel S; Liu L; St-Georges D
    Cardiovasc Res; 1998 Mar; 37(3):627-35. PubMed ID: 9659446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azimilide dihydrochloride, a novel antiarrhythmic agent.
    Karam R; Marcello S; Brooks RR; Corey AE; Moore A
    Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
    Drexler AP; Micklas JM; Brooks RR
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):848-55. PubMed ID: 8961084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of azimilide and d,l-sotalol on the heart rate and blood pressure response to isoproterenol in anesthetized rats.
    Mittelstadt SW; Maynard AE; Benn DR; Lowe ER; Kostreva DR
    Cardiovasc Drugs Ther; 1997 Sep; 11(4):591-8. PubMed ID: 9358964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A benefit-risk assessment of class III antiarrhythmic agents.
    Elming H; Brendorp B; Pehrson S; Pedersen OD; Køber L; Torp-Petersen C
    Expert Opin Drug Saf; 2004 Nov; 3(6):559-77. PubMed ID: 15500415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antiarrhythmic drugs for the treatment of atrial fibrillation.
    Castro A; Bianconi L; Santini M
    Pacing Clin Electrophysiol; 2002 Feb; 25(2):249-59. PubMed ID: 11916001
    [No Abstract]   [Full Text] [Related]  

  • 14. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
    Camm AJ; Pratt CM; Schwartz PJ; Al-Khalidi HR; Spyt MJ; Holroyde MJ; Karam R; Sonnenblick EH; Brum JM;
    Circulation; 2004 Mar; 109(8):990-6. PubMed ID: 14967728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer antiarrhythmic drugs.
    Gupta AK; Maheshwari A; Thakur RK; Lokhandwala YY
    Indian Heart J; 2001; 53(3):354-60. PubMed ID: 11516042
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral class III antiarrhythmics: what is new?
    Khan MH
    Curr Opin Cardiol; 2004 Jan; 19(1):47-51. PubMed ID: 14688634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azimilide for atrial fibrillation: clinical trial results and implications.
    Pritchett EL; Marcello SR
    Card Electrophysiol Rev; 2003 Sep; 7(3):215-9. PubMed ID: 14739716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in the clinical use of anti-arrhythmic drugs (I)].
    Li WZ
    Zhonghua Er Ke Za Zhi; 2003 Oct; 41(10):735-7. PubMed ID: 14731351
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of isoproterenol-induced tachycardia by azimilide in the isolated perfused guinea pig heart.
    Miller KE; Carpenter JF; Brooks RR
    Cardiovasc Drugs Ther; 1998 Mar; 12(1):83-91. PubMed ID: 9607136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs.
    Knobloch K; Brendel J; Rosenstein B; Bleich M; Busch AE; Wirth KJ
    Med Sci Monit; 2004 Jul; 10(7):BR221-8. PubMed ID: 15232496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.